Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Safety, Tolerability, and Immunogenicity Study of GLS-6150 in Healthy Volunteers and in Persons Previously Treated for Hepatitis C Virus Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03674125
Recruitment Status : Completed
First Posted : September 17, 2018
Last Update Posted : May 27, 2020
Sponsor:
Collaborator:
Inovio Pharmaceuticals
Information provided by (Responsible Party):
GeneOne Life Science, Inc.

Brief Summary:
Hepatitis C virus (HCV) is an enveloped, single strand, positive sense RNA flavivirus. Infection by HCV is typically chronic, although an estimated ~10-20% may spontaneously clear the virus. HCV affects between 1.3 - 2 billion individuals, or 2-3% of the global population. HCV has a seroprevalence of approximately 1% in developed countries such as the US and Korea. Chronic HCV infection leads to hepatic fibrosis and cirrhosis. This Phase I study will evaluate the safety, tolerability and immunogenicity of GLS-6150 administered intradermally (ID) followed by electroporation at 1.0 mg and 2.0 mg/dose assessing 3 and 4-dose regimens.

Condition or disease Intervention/treatment Phase
HCV Infection Biological: GLS-6150 Phase 1

Detailed Description:
HCV-003 will assess the safety and immunogenicity of GLS-6150 in those previously treated for HCV infection and who have achieved a sustained virologic response (SVR). This study will provide information as to whether GLS-6150 may be useful to prevent re-infection for those successfully cleared of HCV infection. GLS-6150 is a DNA plasmid vaccine that expresses the NS3/4A gene of HCV, NS4B gene of HCV, the NS5A gene of HCV and IL-28B. GLS-6150 will be administered at one of two dose levels (1 mg or 2 mg) and given as a 2 or 3 vaccination priming regimen with a boost vaccination given at 6 months. Immune T cell and serologic responses will be determined after each dose.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Multi-center, Open-label, Dose-ranging, Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of GLS-6150, Administered ID and Followed by Cellectra® 2000 Healthy Adults and in Persons Previously Treated for Hepatitis C Virus Infection.
Actual Study Start Date : September 4, 2018
Actual Primary Completion Date : April 7, 2020
Actual Study Completion Date : May 4, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Group 1
GLS-6150 at 2.0 mg DNA/dose (3 dose prime plus boost)
Biological: GLS-6150
Group 1: GLS-6150 2.0 mg at 0, 4, 12, and 24 weeks (N=8, healthy volunteers); Group 2: GLS-6150 1.0 mg at 0, 4, 12, and 24 weeks (N=8, previously treated for HCV infection); Group 3: GLS-6150 2.0 mg at 0, 4, 12, and 24 weeks (N=8, previously treated for HCV infection); Group 4: GLS-6150 2.0 mg at 0, 8, and 24 weeks (N=8, previously treated for HCV infection)

Experimental: Group 2
GLS-6150 at 1.0 mg DNA/dose (3 dose prime plus boost)
Biological: GLS-6150
Group 1: GLS-6150 2.0 mg at 0, 4, 12, and 24 weeks (N=8, healthy volunteers); Group 2: GLS-6150 1.0 mg at 0, 4, 12, and 24 weeks (N=8, previously treated for HCV infection); Group 3: GLS-6150 2.0 mg at 0, 4, 12, and 24 weeks (N=8, previously treated for HCV infection); Group 4: GLS-6150 2.0 mg at 0, 8, and 24 weeks (N=8, previously treated for HCV infection)

Experimental: Group 3
GLS-6150 at 2.0 mg DNA/dose(3 dose prime plus boost)
Biological: GLS-6150
Group 1: GLS-6150 2.0 mg at 0, 4, 12, and 24 weeks (N=8, healthy volunteers); Group 2: GLS-6150 1.0 mg at 0, 4, 12, and 24 weeks (N=8, previously treated for HCV infection); Group 3: GLS-6150 2.0 mg at 0, 4, 12, and 24 weeks (N=8, previously treated for HCV infection); Group 4: GLS-6150 2.0 mg at 0, 8, and 24 weeks (N=8, previously treated for HCV infection)

Experimental: Group 4
GLS-6150 at 2.0 mg DNA/dose(2 dose prime plus boost)
Biological: GLS-6150
Group 1: GLS-6150 2.0 mg at 0, 4, 12, and 24 weeks (N=8, healthy volunteers); Group 2: GLS-6150 1.0 mg at 0, 4, 12, and 24 weeks (N=8, previously treated for HCV infection); Group 3: GLS-6150 2.0 mg at 0, 4, 12, and 24 weeks (N=8, previously treated for HCV infection); Group 4: GLS-6150 2.0 mg at 0, 8, and 24 weeks (N=8, previously treated for HCV infection)




Primary Outcome Measures :
  1. Incidence of adverse events [ Time Frame: Day0 through up to 28 weeks ]
  2. Administration (injection) site reactions [ Time Frame: Day0 through up to 28 weeks ]
  3. Changes in safety laboratory parameters described by frequency and severity grade [ Time Frame: Day0 through up to 28 weeks ]

Secondary Outcome Measures :
  1. Antigen specific cellular immune responses to Hepatitis C virus as determined by Interferon-gamma (IFN-γ) ELISpot and/or FACS assay [ Time Frame: Day0 through up to 28 weeks ]
  2. Binding antibody titers to the HCV non-structural proteins (NS3, NS4, NS5) measured by ELISA [ Time Frame: Day0 through up to 28 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Age 19-65 years;
  2. HCV seronegative (Group 1 only), HCV seropositive (Groups 2, 3, 4 only)
  3. Prior treatment for genotype 1a or 1b Hepatitis C infection with treatment ending (12 weeks after end of DAA treatment, 24 weeks after end of combination treatment with Ribavirin/Interferon) prior to study enrollment and with documented achievement of HCV viral clearance (multiple episodes of treatment for Hepatitis C are allowed, Groups 2, 3, 4 only)
  4. Hepatitis C virus PCR negative at screen
  5. Able to provide consent to participate and having signed an Informed Consent Form (ICF);
  6. Able and willing to comply with all study procedures;
  7. Women of child-bearing potential agree to use medically effective contraception (oral contraception, barrier methods, spermicide, etc.) or have a partner who is sterile during this trial, or have a partner who is medically unable to induce pregnancy.
  8. Normal screening ECG or screening ECG with no clinically significant findings;
  9. Screening laboratory must be within normal limits or have only Grade 0-1 findings;
  10. No history of clinically significant immunosuppressive or autoimmune disease.
  11. Not currently or within the previous 4 weeks taking immunosuppressive agents (excluding inhaled, topical skin and/or eye drop-containing corticosteroids, low-dose methotrexate, or prednisone at a dose less than 10 mg/day, or a steroid equivalent).

Exclusion Criteria:

  1. Administration of an investigational compound either currently or within 3 months of first dose;
  2. Administration of any vaccine (excluding influenza vaccination) within 4 weeks of first dose;
  3. Administration of any monoclonal or polyclonal antibody product within 4 weeks of the first dose
  4. Administration of any blood product within 3 months of first dose;
  5. Pregnancy or breast feeding or plans to become pregnant during the course of the study;
  6. History of positive serologic test for HIV, hepatitis B surface antigen (HBsAg); or any potentially communicable infectious disease as determined by the Principal Investigator or Medical Monitor;
  7. Positive Hepatitis C serology performed at baseline (Group 1 only)
  8. Positive screening PCR test for hepatitis C virus;
  9. History of HCV infection with other than genotype 1a or 1b (Group 2, 3 and 4 only)
  10. Baseline evidence of kidney disease as measured by creatinine greater than 1.5 mg/dL
  11. Baseline screening lab(s) with Grade 2 or higher abnormality;
  12. Chronic liver disease, cirrhosis, hemochromatosis, Wilson's disease, alcoholic liver disease, autoimmune hepatitis, or α-1 antitrypsin deficiency(In case of cirrhosis, the person who has been judged F4 grade in Fibroscan);
  13. Immunosuppressive illness including hematologic malignancy, history of solid organ or bone marrow transplantation;
  14. Current or anticipated concomitant immunosuppressive therapy (excluding inhaled, topical skin and/or eye drop-containing corticosteroids, low-dose methotrexate, or prednisone at a dose equal to or greater than 10 mg/day, or steroid equivalent);
  15. Current or anticipated treatment with TNF-α inhibitors such as infliximab, adalimumab, etanercept;
  16. Prior major surgery or any radiation therapy within 4 weeks of the first vaccination;
  17. Any pre-excitation syndromes, e.g., Wolff-Parkinson-White syndrome; history of PSVT syndrome, history of prolonged QT syndrome;
  18. Presence of a cardiac pacemaker or automatic implantable cardioverter defibrillator (AICD)
  19. Metal implants within 20 cm of the planned site(s) of injection;
  20. Presence of keloid scar formation or hypertrophic scar as a clinically significant medical condition at the planned site(s) of injection.
  21. Prisoner or subjects who are compulsorily detained (involuntary incarceration) for treatment of either a physical or psychiatric illness;
  22. Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements or assessment of immunologic endpoints; or
  23. Not willing to allow storage and future use of samples for Hepatitis C virus related research
  24. Any illness or condition that in the opinion of the investigator may affect the safety of the subject or the evaluation of any study endpoint.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03674125


Locations
Layout table for location information
Korea, Republic of
Pusan National University Hospital
Busan, Korea, Republic of
Yonsei University Health System, Severance Hospital
Seoul, Korea, Republic of
Sponsors and Collaborators
GeneOne Life Science, Inc.
Inovio Pharmaceuticals
Layout table for additonal information
Responsible Party: GeneOne Life Science, Inc.
ClinicalTrials.gov Identifier: NCT03674125    
Other Study ID Numbers: HCV-003
First Posted: September 17, 2018    Key Record Dates
Last Update Posted: May 27, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by GeneOne Life Science, Inc.:
Hepatitis C Virus
HCV
Vaccine
DNA
Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Communicable Diseases
Hepatitis C
Hepatitis
Virus Diseases
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
RNA Virus Infections
Flaviviridae Infections